Search
for
Sort by
Research 30 of 1000+
- Severe Hair Loss of the Scalp due to a Hair Dye Containing Para phenylenediamine
- Severe hair loss associated with psyc hotropic drugs in psychiatric inpatients—Data from an observational pharmacovigilance program in German-speaking countries
- Severe hair loss induced by anthrax vaccine and reversed by the treatment with zinc
- Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery
- Severe diffuse non-scarring hair loss in systemic lupus erythematosus - clinical and histopathological analysis of four cases
- Histologic and Cell Kinetic Studies of Hair Loss and Subsequent Recovery Process of Human Scalp Hair Follicles Grafted onto Severe Combined Immunodeficient Mice
- 222 Severe COVID-19 infection predisposes patients to greater burden of hair loss
- 420 Severe thiopurine-induced myelotoxicity and hair loss in Japanese patients with NUDT15 gene variant: A retrospective case-control study
- Azathioprine‐induced severe myelosuppression accompanied by massive hair loss and painful oral ulcer in an autoimmune hepatitis patient with <i>NUDT15</i> minor variant: A case report
- Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
- Poster 148 Severe Hair Loss during Inpatient Rehabilitation due to Telogen Effluvium: A Case Report
- Reply to: ‘Severe diffuse non-scarring hair loss in systemic lupus erythematosus - clinical and histopathological analysis of four cases’
- PCR108 QUALITATIVE AND PSYCHOMETRIC EVALUATION OF THE CLINRO MEASURE FOR EYEBROW HAIR LOSS AND CLINRO MEASURE FOR EYELASH HAIR LOSS IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA
- Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management
- Exhaustive analysis of scalp hair regression: subjective and objective perception from initial hair loss to severe miniaturisation and drug-induced regrowth
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- 75122 Real-world Effectiveness of Baricitinib for Severe Alopecia Areata by Baseline Hair Loss and Episode Duration: Results from a Prospective Observational Study
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- Spontaneous hair regrowth in eight patients with severe alopecia areata
- Hair Loss as a Late Complication of Multisystem Inflammatory Syndrome in Children
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Cases: Severe burns to scalp caused by hair bleaching
- The changing landscape of managing hair loss: a 30‐year perspective
- Hair Transplant Cost in India
- Eosinophilia versus atopy as a predictor of severe phenotypes in alopecia areata
- Hair and nail adverse events during treatment with target therapies for metastatic melanoma
- A prospective cross-sectional study on post COVID-19 hair loss at a tertiary care hospital